CEO Daniel Barber highlighted that "we are now less than 6 months away from our FDA action date for Anaphylm epinephrine sublingual film, potentially the first and only oral product for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback